Cargando…

Modified IDSA/ATS minor criteria for severe community-acquired pneumonia best predicted mortality: Notification

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Notification
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831418/ https://www.ncbi.nlm.nih.gov/pubmed/31415439 http://dx.doi.org/10.1097/MD.0000000000016914

Ejemplares similares

Modified IDSA/ATS Minor Criteria for Severe Community-Acquired Pneumonia Best Predicted Mortality
por: Li, Hai-yan, et al.
Publicado: (2015)

Notification
Publicado: (2023)

Modified IDSA/ATS minor criteria for severe community-acquired pneumonia best predicted mortality: Erratum
Publicado: (2017)

Notification that new names and new combinations have appeared in volume 63, part 6, of the IJSEM
Publicado: (2013)

Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia
por: Egger, Michael E., et al.
Publicado: (2016)

Cold-inducible RNA-binding protein might determine the severity and the presences of major/minor criteria for severe community-acquired pneumonia and best predicted mortality
por: Guo, Qi, et al.
Publicado: (2020)

Scored minor criteria for severe community-acquired pneumonia predicted better
por: Guo, Qi, et al.
Publicado: (2019)

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
por: Nahid, Payam, et al.
Publicado: (2019)

Correction to: Scored minor criteria for severe community-acquired pneumonia predicted better
por: Guo, Qi, et al.
Publicado: (2019)

Erratum: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Publicado: (2020)

ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
por: Chang, Kwok-Chiu, et al.
Publicado: (2020)

What is new in BTS 2017 & ATS/ERS/ESCMID/IDSA 2020 guidelines on treatment of non-tuberculous mycobacterial pulmonary disease?
por: Sharma, Surendra Kumar, et al.
Publicado: (2021)

1466. Adherence to Empiric Treatment Recommended by IDSA/PIDS Pediatric Community-Acquired Pneumonia (CAP) Guidelines According to Immunization Status
por: Thomas, Lindsay, et al.
Publicado: (2018)

489. Validation of the SHEA/IDSA Severity Criteria to Predict Poor Outcomes Among Inpatients and Outpatients With Clostridium difficile Infection
por: Stevens, Vanessa, et al.
Publicado: (2018)

Minor Criteria of Infectious Disease Society of America/American Thoracic Society for Severe Community-Acquired Pneumonia Can Predict Delayed Treatment Response
por: Park, So Young, et al.
Publicado: (2012)

Severe community-acquired pneumonia: risk factors for in-hospital mortality
por: Pereira, JM, et al.
Publicado: (2012)

Impact of microbial Aetiology on mortality in severe community-acquired pneumonia
por: Quah, Jessica, et al.
Publicado: (2018)

IDSA Ebola Summary—August 2014
por: Murray, Barbara E., et al.
Publicado: (2014)

Severe community-acquired pneumonia
por: Morgan, AJ, et al.
Publicado: (2016)

Severe Community-Acquired Pneumonia
por: Khatib, Khalid, et al.
Publicado: (2019)

Severe Community-Acquired Pneumonia
por: Sligl, Wendy I., et al.
Publicado: (2013)

Severe community-acquired pneumonia
por: Niederman, Michael S., et al.
Publicado: (2022)

1655 Lack of Adherence to SHEA-IDSA Treatment Guidelines for Severe Clostridium difficile Infection is Associated with Increased Mortality
por: Patel, Ishan, et al.
Publicado: (2014)

Severe community acquired pneumonia update: mortality, mechanisms and medical intervention
por: Laterre, Pierre-Francois
Publicado: (2008)

Experience with the ATS optics
por: Fartoukh, S
Publicado: (2017)

ATS MD’s in 2016
por: Fartoukh, Stephane, et al.
Publicado: (2016)

NRITLD-ATS 2012
por: Masjedi, Mohammad Reza, et al.
Publicado: (2012)

Criteria of the systemic inflammatory response syndrome in patients with community-acquired pneumonia
por: Ustyantseva, I, et al.
Publicado: (2006)

What is the Role of Respiratory Viruses in Community-Acquired Pneumonia?: What is the Best Therapy for Influenza and Other Viral Causes of Community-Acquired Pneumonia?
por: Pavia, Andrew T.
Publicado: (2013)

Advances in severe community-acquired pneumonia
por: Wang, Jian, et al.
Publicado: (2019)

Ceftaroline in severe community-acquired pneumonia
por: Cilloniz, Catia, et al.
Publicado: (2022)

Mortality of Community-Acquired Pneumonia in Korea: Assessed with the Pneumonia Severity Index and the CURB-65 Score
por: Kim, Hye In, et al.
Publicado: (2013)

Analysis of the mortality rate in patients admitted to the ICU for severe community-acquired pneumonia
por: Joya-Montosa, C, et al.
Publicado: (2015)

Using Data-Driven Rules to Predict Mortality in Severe Community Acquired Pneumonia
por: Wu, Chuang, et al.
Publicado: (2014)

Diagnostic accuracy of neutrophil counts in histopathological tissue analysis in periprosthetic joint infection using the ICM, IDSA, and EBJIS criteria
por: Sigmund, Irene K., et al.
Publicado: (2021)

Emerging infectious diseases featured at ICAAC/IDSA meeting.
Publicado: (1995)

ATS and our Journal Collaboration
por: Mortaz, Esmaeil
Publicado: (2012)

Can we recognize severe community-acquired pneumonia without pneumonia severity index? Use of modified qSOFA with procalcitonin
por: Güleç, Tolgahan, et al.
Publicado: (2023)

Middle molecules in severe community-acquired pneumonia
por: Dumitras, T, et al.
Publicado: (2015)

Factors influencing severity of community-acquired pneumonia
por: Mahendra, M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9lq65v07uhfq4o72lscbr7q1r7